- Retatrutide is described in published literature as a GIP, GLP-1, and glucagon receptor agonist
- It has been studied in clinical research settings related to obesity and type 2 diabetes in phase 2 trials
- Published findings should not be interpreted as instructions for personal use
- CoreVials materials are offered for laboratory research use only — not for human consumption or medical use
Sources: Jastreboff AM et al., NEJM 2023; Ludvik B et al., Lancet 2023.
What Is Retatrutide in Research Literature?
Retatrutide has been described in published research as a triple hormone receptor agonist — a compound that interacts with three distinct receptor systems: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors.
This description comes from peer-reviewed literature including a phase 2 study published in The New England Journal of Medicine (Jastreboff AM et al., 2023). The study was conducted in a formal clinical research setting and evaluated the compound in people with obesity.
Separately, a phase 2 study published in The Lancet (Ludvik B et al., 2023) investigated retatrutide in people with type 2 diabetes and reported findings related to glycemic and body weight outcomes in that clinical context.
This page summarizes the published literature. It is not a treatment recommendation, dosing guide, or personal health suggestion.
Receptor Activity Studied in Research
The three receptor systems described in published retatrutide literature each play a role in metabolic and endocrine signaling:
| Receptor | Full Name | General Research Area |
|---|---|---|
| GIP | Glucose-Dependent Insulinotropic Polypeptide | Incretin biology, metabolic signaling |
| GLP-1 | Glucagon-Like Peptide-1 | Incretin biology, glucose-related signaling |
| Glucagon | Glucagon Receptor | Energy balance, hepatic glucose signaling |
These receptor descriptions are from the published research literature. Listing receptor activity here does not imply any claim about what this compound does for any individual.
Research Context
Retatrutide has been evaluated in structured clinical research phases — specifically phase 2 trials — meaning it has been studied in human research participants under controlled conditions as part of a formal regulatory development pathway. This is distinct from having received FDA approval.
- A phase 2 trial evaluates preliminary safety and activity in a defined patient population, typically before larger phase 3 studies.
- Phase 2 data does not constitute regulatory approval or a determination of safety and effectiveness for general use.
- The compound is described in literature as investigational — meaning it is being researched, not yet approved for any indication in the U.S.
CoreVials does not sell retatrutide or any research compound for human consumption, medical treatment, diagnosis, or personal use.
This page is educational. It does not provide dosing, administration, injection, reconstitution, or medical guidance of any kind.
If you are seeking treatment for obesity, type 2 diabetes, or any medical condition, consult a licensed healthcare provider.
Why Approved Medicines and RUO Materials Are Different
Published clinical research about a compound does not make a RUO catalog version of that compound an approved medicine. The distinction is important:
Related Research Topics
- → What Are Peptides? A Simple Beginner's Guide
- → What Does RUO Mean? Research Use Only Explained
- → Common Research Compound Categories
- → Peptides & Research Compounds, Explained Simply
Explore Related RUO Research Materials
Qualified buyers can review available CoreVials research materials in the RUO catalog. Product listings are for laboratory research use only and are not intended for human consumption.
